- Efficient large-scale synthesis of 5′-O-dimethoxytrityl-N 4-benzoyl-5-methyl-2′-deoxycytidine
-
An efficient process to synthesize 5′- O -dimethoxytrityl-N 4 -benzoyl-5-methyl-2 ′-deoxycytidine in high yield and quality is described. Final benzoylation was improved by developing a method to selectively hydrolyze benzoyl ester impurities. This inexpensive approach was scaled up to multi-kilogram quantities for routine use in oligonucleotide therapeutics. Copyright Taylor & Francis Group, LLC.
- Ross, Bruce,Han, Mingming,Ravikumar, Vasulinga
-
p. 765 - 770
(2007/10/03)
-
- Antisense inhibition via RNAse H-independent reduction in mRNA
-
The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.
- -
-
Page/Page column 20
(2010/02/12)
-
- Antisense modulation of resistin expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of resistin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding resistin. Methods of using these compounds for modulation of resistin expression and for treatment of diseases associated with expression of resistin are provided.
- -
-
Page/Page column 17-18
(2010/02/05)
-
- Modulation of forkhead box O1A expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
- -
-
Page/Page column 20
(2010/02/06)
-
- Antisense modulation of phosphotyrosyl phosphatase activator expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of phosphotyrosyl phosphatase activator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphotyrosyl phosphatase activator. Methods of using these compounds for modulation of phosphotyrosyl phosphatase activator expression and for treatment of diseases associated with expression of phosphotyrosyl phosphatase activator are provided.
- -
-
Page/Page column 17-18
(2008/06/13)
-
- Antisense modulation of PPP2R1A expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of PPP2R1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPP2R1A. Methods of using these compounds for modulation of PPP2R1A expression and for treatment of diseases associated with expression of PPP2R1A are provided.
- -
-
Page/Page column 17-18
(2010/02/05)
-
- Antisense modulation of requiem expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of requiem. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding requiem. Methods of using these compounds for modulation of requiem expression and for treatment of diseases associated with expression of requiem are provided.
- -
-
Page/Page column 17-18
(2010/02/05)
-
- Antisense modulation of hepatoma-derived growth factor expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of hepatoma-derived growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hepatoma-derived growth factor. Methods of using these compounds for modulation of hepatoma-derived growth factor expression and for treatment of diseases associated with expression of hepatoma-derived growth factor are provided.
- -
-
Page/Page column 17-18
(2010/11/30)
-
- Antisense modulation of PTPRA expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of PTPRA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPRA. Methods of using these compounds for modulation of PTPRA expression and for treatment of diseases associated with expression of PTPRA are provided.
- -
-
Page/Page column 18
(2008/06/13)
-
- Antisense modulation of Ran GTPase activating protein 1 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of Ran GTPase activating protein 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ran GTPase activating protein 1. Methods of using these compounds for modulation of Ran GTPase activating protein 1 expression and for treatment of diseases associated with expression of Ran GTPase activating protein 1 are provided.
- -
-
Page/Page column 18
(2010/02/05)
-
- Antisense modulation of KIAA1531 protein expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of KIAA1531 protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding KIAA1531 protein. Methods of using these compounds for modulation of KIAA1531 protein expression and for treatment of diseases associated with expression of KIAA1531 protein are provided.
- -
-
Page/Page column 18
(2010/02/05)
-
- Antisense modulation of G protein-coupled receptor 6 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 6. Methods of using these compounds for modulation of G protein-coupled receptor 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor 6 are provided.
- -
-
Page/Page column 18
(2010/02/05)
-
- Antisense modulation of LAR expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of LAR. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding LAR. Methods of using these compounds for modulation of LAR expression and for treatment of diseases associated with expression of LAR are provided.
- -
-
Page/Page column 18
(2010/02/05)
-
- Antisense modulation of G protein-coupled receptor 12 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 12. Methods of using these compounds for modulation of G protein-coupled receptor 12 expression and for treatment of diseases associated with expression of G protein-coupled receptor 12 are provided.
- -
-
Page/Page column 18
(2010/11/30)
-
- Antisense modulation of fatty acid synthase expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of fatty acid synthase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fatty acid synthase. Methods of using these compounds for modulation of fatty acid synthase expression and for treatment of diseases associated with expression of fatty acid synthase are provided.
- -
-
Page/Page column 17-18
(2010/02/06)
-
- Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, type II beta expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of phosphatidylinositol-4-phosphate 5-kinase, type II beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphatidylinositol-4-phosphate 5-kinase, type II beta. Methods of using these compounds for modulation of phosphatidylinositol-4-phosphate 5-kinase, type II beta expression and for treatment of diseases associated with expression of phosphatidylinositol-4-phosphate 5-kinase, type II beta are provided.
- -
-
-
- Antisense modulation of hypothetical tumor endothelial marker expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of hypothetical tumor endothelial marker. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hypothetical tumor endothelial marker. Methods of using these compounds for modulation of hypothetical tumor endothelial marker expression and for treatment of diseases associated with expression of hypothetical tumor endothelial marker are provided.
- -
-
-
- Antisense modulation of PTPN12 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of PTPN12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN12. Methods of using these compounds for modulation of PTPN12 expression and for treatment of diseases associated with expression of PTPN12 are provided.
- -
-
-
- Phosphatidylinositol-4-phosphate 5-kinase, type II beta inhibitors for inhibiting angiogenesis
-
Compounds, compositions and methods are provided for modulating the expression of phosphatidylinositol-4-phosphate 5-kinase, type II beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, type II beta. Methods of using these compounds for modulation of phosphatidylinositol-4-phosphate 5-kinase, type II beta expression and for diagnosis and treatment of disease associated with expression of phosphatidylinositol-4-phosphate 5-kinase, type II beta are provided.
- -
-
-
- Antisense modulation of PRL-3 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of PRL-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PRL-3. Methods of using these compounds for modulation of PRL-3 expression and for treatment of diseases associated with expression of PRL-3 are provided.
- -
-
-
- Antisense modulation of transcription factor DP-1 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of transcription factor Dp-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding transcription factor Dp-1. Methods of using these compounds for modulation of transcription factor Dp-1 expression and for treatment of diseases associated with expression of transcription factor Dp-1 are provided.
- -
-
-
- Antisense modulation of DRAK1 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of DRAK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding DRAK1. Methods of using these compounds for modulation of DRAK1 expression and for treatment of diseases associated with expression of DRAK1 are provided.
- -
-
-
- Extracellular-signal-regulated kinase-6 inhibitors for inhibiting angiogenesis
-
Compounds, compositions and methods are provided for modulating the expression of extracellular-signal-regulated kinase-6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding extracellular-signal-regulated kinase-6. Methods of using these compounds for modulation of extracellular-signal-regulated kinase-6 expression and for diagnosis and treatment of disease associated with expression extracellular-signal-regulated kinase-6 are provided.
- -
-
-
- Antisense modulation of splicing factor R/S-rich 10 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of splicing factor R/S-rich 10. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding splicing factor R/S-rich 10. Methods of using these compounds for modulation of splicing factor R/S-rich 10 expression and for treatment of diseases associated with expression of splicing factor R/S-rich 10 are provided.
- -
-
Page column 18-19
(2010/02/03)
-
- Antisense modulation of G protein-coupled receptor 49 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 49. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 49. Methods of using these compounds for modulation of G protein-coupled receptor 49 expression and for treatment of diseases associated with expression of G protein-coupled receptor 49 are provided.
- -
-
-
- OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS
-
Disclosed are oligonucleotides and oligonucleosides that include one or more modified nucleoside units. The oligonucleotides and oligonucleosides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.
- -
-
Page 219-221
(2010/02/04)
-
- Antisense modulation of orphan G-protein coupled receptor GPRC5B expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of orphan G-protein coupled receptor GPRC5B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding orphan G-protein coupled receptor GPRC5B. Methods of using these compounds for modulation of orphan G-protein coupled receptor GPRC5B expression and for treatment of diseases associated with expression of orphan G-protein coupled receptor GPRC5B are provided.
- -
-
-
- Antisense modulation of heme oxygenase 1 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of heme oxygenase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding heme oxygenase 1. Methods of using these compounds for modulation of heme oxygenase 1 expression and for treatment of diseases associated with expression of heme oxygenase 1 are provided.
- -
-
-
- Antisense modulation of extracellular-signal-regulated kinase-6 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of extracellular-signal-regulated kinase-6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding extracellular-signal-regulated kinase-6. Methods of using these compounds for modulation of extracellular-signal-regulated kinase-6 expression and for treatment of diseases associated with expression of extracellular-signal-regulated kinase-6 are provided.
- -
-
-
- Antisense modulation of G protein-coupled receptor 39 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 39. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 39. Methods of using these compounds for modulation of G protein-coupled receptor 39 expression and for treatment of diseases associated with expression of G protein-coupled receptor 39 are provided.
- -
-
-
- Antisense modulation of profilin 1 expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of profilin 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding profilin 1. Methods of using these compounds for modulation of profilin 1 expression and for treatment of diseases associated with expression of profilin 1 are provided.
- -
-
-
- Antisense modulation of centromere protein B expression
-
Antisense compounds, compositions and methods are provided for modulating the expression of Centromere protein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Centromere protein B. Methods of using these compounds for modulation of Centromere protein B expression and for treatment of diseases associated with expression of Centromere protein B are provided.
- -
-
-